Share This:
https://ntp.niehs.nih.gov/go/imm96006abs

Abstract for IMM96006

28-day Dose Range-Finding Study for the Immunotoxicity Evaluation of Thalidomide in Female B6C3F1 Mice

CASRN: 50-35-1
Chemical Formula: C13H10N2O4
Molecular Weight: 258.232
Report Date: August 1989

Abstract

The following abstract presents results of a study conducted by a contract laboratory for the National Toxicology Program. The findings have not been peer reviewed and were not evaluated in accordance with the levels of evidence criteria established by NTP in March 2009. The findings and conclusions for this study should not be construed to represent the views of the NTP or the U.S. Government.

Thalidomide (TLM) is presently being suggested in the treatment of immune-related diseases, in particular, the treatment of AIDS patients. In the 1960's TLM was used in Europe as a sedative and taken off the market when fetal abnormalities were discovered.

The purpose of these studies was to establish the potential effects of TLM on the immune system. These studies were conducted in female B6C3F1 mice. The animals were treated with TLM for 28 days by the intraperitoneal route. TLM was prepared daily at doses of 30, 100 and 150 mg/kg in sterile distilled water.

The baseline toxicology studies are summarized in Table ES-1. Mice treated with TLM at doses of 30, 100 and 150 mg/kg had no significant changes in body weight when evaluated over the four week treatment period. No significant effects were seen in body weight change with the exception of a statistically significant decrease in body weight gain of 23% for Day 22-1. No statistically significant effects were observed on organ weights - liver, spleen, lungs, thymus and kidneys, nor the hematology parameters - erythrocytes, hemoglobin, hematocrit, leukocyte numbers, leukocyte differentials, reticulocytes, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentrations and platelets.

Table ES-2 summarizes the immunology studies. When the data were expressed as absolute values, there was no statistically significant difference in B cells, T cells or CD4 cells with treatment of TLM. TLM treatment increased by 23% the number of CD4-CD8+ cells in the T cell subsets and decreased by 11% the number of NK1.1+CD3- cells at the highest dosage (150 mg/kg/day). The AFC response was increased by 37% and 42% for AFC/106 spleen cells (specific activity) and AFC/spleen (total spleen activity), respectively, at the highest dose (150 mg/kg/day) tested. TLM treatment had no effect on serum IgM titers. A significant increase was seen in the CTL response at 1.5:1, 3:1 and 6:1 E:T ratios. No biologically significant effects were seen in either the NK cell activity or the MLR response.

The results of the host resistance study are summarized in Table ES-3. Host resistance to Listeria monocytogenes was not affected.

In summary, thalidomide in doses of 30, 100 and 150 mg/kg, administered for 28 days by the intraperitoneal route, produced a slight increase in humoral and cellular immune indicators.

Studies

Table ES-1
Summary Table for Toxicology Studies
TLM-28-1M-IP

 

Parameter Result Maximum Effect Dose Comment
Body Weight
Day 8 No Effect
Day 15 No Effect
Day 22 No Effect
Day 29 No Effect
Weight Changes
Day 8-1 No Effect
Day 15-1 No Effect
Day 22-1 Decreased -23% 100 mg/kg
Day 29-1 No Effect

 

Pathology
Gross Pathology No Effect
Histopathology Not Done
Organ Weights
Brain No Effect
Liver No Effect
Spleen No Effect
Lungs No Effect
Thymus No Effect
Kidneys No Effect

 

Hematology
RBCs No Effect
Hemoglobin No Effect
Hematocrit No Effect
MCV No Effect
MCH No Effect
MCHC No Effect
Reticulocytes No Effect
Leukocytes No Effect
Leukocyte Diff
Lymphocytes No Effect
Neutrophils No Effect
Eosinophils No Effect

 

Table ES-2
Summary Table for Immunology Studies
TLM-28-1M-PO

 

Parameter Results Maximum Effect Dose Comment

 

Surface Markers/Absolute Values
Ig+ No Effect
CD3+ No Effect
CD4+CD8- No Effect
CD4-CD8+ Increased 23% Dose Dependent
CD4+CD8+ No Effect
NK1.1+CD3- Decreased 11% 150 mg/kg Dose Dependent
MAC-3+ No Effect

 

IgM Humoral Immune Response to Sheep Erythrocytes
IgM AFC to sRBC Increased 42% 150 mg/kg Total Spleen Activity
Serum Titers to

sRBC

No Effect

 

Mixed Leukocyte Response
MLR No Effect

 

Cytotoxic T Lymphocyte Activity
CTL Increased 121% 150 mg/kg 1.5:1 Ratio

 

NK Cell Activity
100:1 No Effect

 


 

Table ES-3
Summary Table for Host Resistance Studies
TLM-28-IM-PO

 

Parameter Results Maximum Effect Dose Comment

 

Listeria monocytogenes No Effect